HP
HealthInvest Partners Portfolio holdings
AUM $234M
1-Year Return
10.88%
This Quarter Return
+6.02%
1 Year Return
+10.88%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$71M
AUM Growth
+$4.2M
(+6.3%)
Cap. Flow
+$6.68M
Cap. Flow
% of AUM
9.41%
Top 10 Holdings %
Top 10 Hldgs %
87.26%
Holding
18
New
1
Increased
9
Reduced
3
Closed
5
Top Buys
| 1 |
McKesson
MCK
|
+$6.46M |
| 2 |
Cardinal Health
CAH
|
+$4.79M |
| 3 |
Cencora
COR
|
+$4.52M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$4.49M |
| 5 |
AbbVie
ABBV
|
+$4.47M |
Top Sells
| 1 |
Supernus Pharmaceuticals
SUPN
|
+$8.93M |
| 2 |
Accuray
ARAY
|
+$7.35M |
| 3 |
Aldeyra Therapeutics
ALDX
|
+$2.72M |
| 4 |
Evolus
EOLS
|
+$2.29M |
| 5 |
Rigel Pharmaceuticals
RIGL
|
+$1.79M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ironwood Pharmaceuticals
IRWD
$211M
| $8.51M | 11.99% |
730,000
+45,000
| +7% | +$525K |
|
|
2
McKesson
MCK
$88.2B
| $8.45M | 11.91% |
34,000
+26,000
| +325% | +$6.46M |
|
3
Harmony Biosciences
HRMY
$1.86B
| $8.32M | 11.72% |
195,000
+10,000
| +5% | +$426K |
|
|
4
AbbVie
ABBV
$379B
| $6.5M | 9.16% |
48,000
+33,000
| +220% | +$4.47M |
|
|
5
Cardinal Health
CAH
$36.1B
| $6.44M | 9.07% |
125,000
+93,000
| +291% | +$4.79M |
|
|
6
Cencora
COR
$57.6B
| $6.38M | 8.99% |
48,000
+34,000
| +243% | +$4.52M |
|
|
7
Bristol-Myers Squibb
BMY
$93.9B
| $6.24M | 8.79% |
100,000
+72,000
| +257% | +$4.49M |
|
8
Utah Medical Products
UTMD
$198M
| $4M | 5.64% |
40,000
-2,000
| -5% | -$200K |
|
|
LJPC
9
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $3.86M | 5.44% |
830,000
+560,000
| +207% | +$2.6M |
|
|
LCI
10
DELISTED
Lannett Company, Inc.
LCI
| $3.24M | 4.57% |
500,000
+56,250
| +13% | +$365K |
|
|
ZGNX
11
DELISTED
Zogenix, Inc.
ZGNX
| $3.17M | 4.47% |
195,000
-25,000
| -11% | -$406K |
|
|
ICPT
12
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $2.98M | 4.2% |
+183,000
| New | +$2.98M |
|
|
13
Rigel Pharmaceuticals
RIGL
$662M
| $2.89M | 4.07% |
109,000
-67,500
| -38% | -$1.79M |
|
|
14
Aldeyra Therapeutics
ALDX
$312M
| – | – |
-310,000
| Closed | -$2.72M |
|
|
15
Accuray
ARAY
$177M
| – | – |
-1,860,000
| Closed | -$7.35M |
|
|
16
Evolus
EOLS
$450M
| – | – |
-300,000
| Closed | -$2.29M |
|
|
17
Supernus Pharmaceuticals
SUPN
$2.47B
| – | – |
-335,000
| Closed | -$8.93M |
|
18
UroGen Pharma
URGN
$840M
| – | – |
-75,000
| Closed | -$1.26M |
|